Explore Supplements Subscribe
The VerdictLOW CONVICTIONVerdict Score 66Worth-It: Poor ROI (32/100)

CBD works at doses your body can't safely take every day — which is the entire problem.

Summary: CBD is one of the most misunderstood supplements on the market. It works — but only at doses far higher than what's in your gummy. The problem is that those effective doses (300mg+) approach the level where 5–6% of healthy adults develop liver damage within a month. The OTC doses people act

  1. Here's what nobody talks about: the doses that actually work (300mg — roughly 10ml of a standard oil) are 150 times higher than what European food safety regulators say is safe to take every day.
  2. What most people get wrong: the gummy or dropper you buy at the health shop (10–50mg) has not been shown to do anything measurable in any human trial — those doses are simply too small to trigger any known mechanism.
  3. What to watch for: if you are buying CBD for sleep, a single 0.3mg melatonin tablet taken before bed has stronger evidence, is 500 times the lower dose, and costs a fraction of the price.

Think of CBD like a medicine that only comes in one pill size — but that pill is 150 times the dose your body can handle safely every day. At 300mg it genuinely pushes a calming switch in the brain (a serotonin receptor called 5-HT1A). The problem is that same dose hits your liver's chemical processing machinery so hard that 1 in 20 healthy adults develop organ stress within a month at 400mg.

That's the general answer. Your stack is different.

Check your whole stack
SH
Dr. Seth Holbrook, DPT — Doctor of Physical Therapy • Coach to 300+ clients
I built The Verdict to cut through recycled health advice and show what the evidence actually supports.

Supplement Engine  ·  Herbal / Botanical Extract

CBD

Cannabidiol — sleep, anxiety, pain: evidence vs marketing

Conditional Skip (most uses)

Scroll

The Plain English Version

CBD works at doses your body can't safely take every day — which is the entire problem.

Think of CBD like a medicine that only comes in one pill size — but that pill is 150 times the dose your body can handle safely every day. At 300mg, it genuinely pushes a calming switch in the brain (a specific serotonin pathway). The problem is that same dose hits your liver's chemical processing machinery so hard that 1 in 20 healthy adults develop organ stress within a month.

  1. Here's what nobody talks about: the doses that actually work (300mg — roughly 10ml of a standard oil) are 150 times higher than what European food safety regulators say is safe to take every day.
  2. What most people get wrong: the gummy or dropper you buy at the health shop (10–50mg) has not been shown to do anything measurable in any human trial — those doses are simply too small to trigger any known mechanism.
  3. What to watch for: if you are buying CBD for sleep, a single 0.3mg melatonin tablet taken before bed has stronger evidence, is roughly 500 times the lower dose, and costs a fraction of the price.

Want the full evidence? Keep scrolling

§3 — Marketing Claims

What People Claim

CBD marketing claims

"A natural solution for pain, sleep, and stress — all the benefits of cannabis without the high."

Pain Relief

A natural alternative to NSAIDs and opioids, reducing chronic and neuropathic pain through anti-inflammatory action — without side effects.

Sleep Aid

Improves sleep quality and duration. Positioned as a "natural melatonin alternative" that is non-habit-forming and free of morning grogginess.

Anxiety Relief

Reduces generalised anxiety, social anxiety, and stress-related burnout by modulating the stress response — without any psychoactive effects.

These three claims drive an enormous OTC market. The marketing is not dishonest about what CBD might do — the problem is the dose required to do it.

§5 — Evidence Review

What the Evidence Shows

CBD evidence overview
Claimed Benefit Evidence Verdict
Anxiety — acute, situational
Masataka 2019 (N=37, 300mg/4wks); Crippa 2021 (N=120, 300mg/28d)		 MODERATE Works — at 300mg single dose only
Anxiety — chronic, generalised
Requires ≥150mg/day; chronic use hits hepatotoxicity ceiling		 WEAK Too risky for daily use
Sleep quality
Saleska 2023: 15mg CBD vs 5mg melatonin (pragmatic RCT)		 WEAK Not superior to melatonin
Sleep architecture at high dose
Shannon 2019 (160mg); multiple actigraphy studies		 WEAK Subjective benefit only — anxiolysis secondary, not sleep architecture change
Chronic pain (monotherapy)
Wang 2021 BMJ — 32 RCTs, N=5,000+		 DEBUNKED –0.50cm on 10cm VAS — below clinical relevance threshold
Anti-inflammation
TRPV1 mechanism exists; unquantified at OTC doses		 WEAK Underdosed at OTC levels — mechanism not activated

What would change the anxiety verdict: Chronic-use RCT at 75–150mg/day with bi-weekly liver monitoring demonstrating safety at sub-hepatotoxic doses over 6+ months.

What would change the pain verdict: Adequately powered RCT showing ≥1cm VAS reduction (minimum clinically important difference) with CBD monotherapy, controlling for placebo and THC content.

–0.50cm

Pain reduction across 32 RCTs (N=5,000+) on a 10cm scale  ·  Minimum clinically important difference: 1–2cm

Key Findings

The dose paradox is the entire story. The therapeutic dose gap is unbridgeable with current evidence: effective doses (300–600mg) exceed EFSA 2025's provisional daily intake limit of 2mg by 150–300 times and approach the liver damage threshold confirmed in healthy adults. STRONG

What would change this: A safe-dose bracket identified by mechanistic dose-finding studies that demonstrates anxiolytic efficacy below the hepatotoxicity floor.

OTC doses of 10–50mg have no demonstrated mechanism of action in any human clinical trial. STRONG

What would change this: A positive Phase II RCT at ≤50mg showing measurable pharmacodynamic effect via validated biomarkers.

§6 — Mechanism

How It Works

CBD mechanism of action

CBD is not a classical cannabinoid agonist. It has very low binding affinity for the CB1 and CB2 receptors that THC targets — which is why it produces no psychoactive effect. Its pharmacological effects come from a different set of targets.

5-HT1A Receptor

At 300mg+, CBD partially activates this serotonin receptor. This is the source of its anxiolytic effect — the only claim with MODERATE evidence. Only active at high acute doses.

TRPV1 Ion Channel

Modulates pain perception channels. Bell-shaped dose response: moderate doses produce analgesic effects; at very high doses this pathway becomes anxiogenic — too much CBD can increase anxiety.

Adenosine Reuptake

Inhibiting adenosine reuptake increases extracellular adenosine, contributing to sedation and anti-inflammatory signalling. This is partly why high-dose CBD is associated with subjective sleepiness.

CYP3A4 / CYP2C19

CBD potently inhibits these liver enzymes. This is NOT a therapeutic mechanism — it is the source of severe drug interactions (clobazam +500%) and the primary pathway for liver damage at therapeutic doses.

The fundamental problem: The only mechanisms with human clinical support require doses that are acutely unsafe for chronic use and now non-compliant with European food safety standards. There is no therapeutic window that is both effective AND safe for daily use.

§8 — Translation Gap

Real World vs Lab

Dose Paradox

The Lab

Clinical trials use pharmaceutical-grade isolate at 150–600mg/day under clinical monitoring with regular liver function tests.

Real World

OTC consumers take 10–50mg/day — doses below any demonstrated mechanism of action threshold in any human trial.

MORE CONSERVATIVE

Product Contamination

The Lab

Clinical trials use ≥98% pure isolate with zero THC — pharmacologically predictable, third-party verified.

Real World

21–35% of commercial CBD products contain detectable THC (Johns Hopkins 2022). Only 24% are accurately labelled. Consumer products are pharmacologically unpredictable.

MORE CONSERVATIVE

Hepatotoxicity Floor — Lower Than Assumed

The Lab

Florian 2025 (JAMA) used 400mg/day — a dose consumers genuinely attempt for anxiety and sleep — with regular liver monitoring.

Real World

5.6% of healthy adults developed liver damage with no external symptoms. The injury went undetected without blood tests. No clinical supervision exists at consumer level.

MORE CONSERVATIVE

§9 — Exactly How to Use It

The Protocol

CBD dosing protocol
Who Dose Timing Form Notes
Acute situational anxiety only
Clinically diagnosed SAD or high-stakes event		 300mg single dose 60–90 min pre-stressor Isolate oil + high-fat meal, or water-soluble No loading. No repeat dosing. Not for daily use.
Chronic / daily anxiety NOT RECOMMENDED — — Chronic hepatotoxicity risk. No safe chronic dose established.
Athletes (competitive) AVOID — — 21–35% of products contain undisclosed THC. WADA strict liability.
OTC general wellness 2mg/day max With high-fat meal Isolate oil only (≥98% purity) EFSA 2025 provisional ADI. No demonstrated efficacy at this dose.

Forms Comparison

Oil Isolate (fed)

~24% absorption

Only reliable form for dose-controlled acute use. Take with high-fat meal — boosts absorption from 6% to 24%.

Water-Soluble

>30% estimated; Cmax ~5.7× vs isolate

Consistent dosing without food dependency — but note the paradox: higher absorption means more CBD hitting the liver per milligram.

SNEDDS / Nanoemulsion

~7× AUC vs standard oil

Pharmaceutical-grade. Highest absorption. Not available OTC in standardised form.

Gummies

Highly variable / poor

Marketing format. Typical doses are sub-threshold. No OTC gummy has demonstrated pharmacological activity.

Full / Broad Spectrum

Unknown — variable THC

Avoid. High THC contamination risk, WADA violation risk, unpredictable pharmacokinetics.

Vapes

Variable — unregulated

Avoid. Unregulated inhalation products. No standardised dose. No safety profile for chronic use.

Absorption tip: A high-fat meal quadruples plasma CBD when using oil isolate. Water-soluble formulations eliminate this food dependency — but do not make CBD safer at therapeutic doses. Higher bioavailability means higher liver exposure per milligram.

§10 — Safety

Safety & Interactions

CBD safety and drug interactions

Drug Interactions — SEVERE

CBD potently inhibits CYP3A4 and CYP2C19 liver enzymes. Any drug cleared by these pathways will accumulate to dangerous levels.

Clobazam (antiepileptic) SEVERE

CYP2C19 inhibition drives active metabolite plasma levels up by up to 500%. Risk of extreme sedation and toxicity. Avoid; requires clobazam dose reduction under physician supervision if co-prescribed (e.g. in Dravet syndrome treatment — the only approved CBD indication).

Valproate / Valproic Acid SEVERE

Hepatotoxic synergy with CBD's direct liver effects — exponentially elevated liver enzyme risk. Contraindicated. Requires frequent liver function monitoring if clinically co-prescribed.

Warfarin (anticoagulant) SEVERE

CYP2C9 inhibition increases warfarin plasma levels → elevated INR → increased bleeding risk. Avoid. Requires frequent INR monitoring if clinician deems use necessary.

Tacrolimus / Sirolimus (immunosuppressants) SEVERE

CYP3A4 + P-glycoprotein inhibition → elevated immunosuppressant levels → organ toxicity risk in transplant patients. Avoid without close clinical supervision.

Alcohol / Benzodiazepines / Opioids MODERATE-HIGH

CNS depression potentiation — increased psychomotor impairment and sedation. Avoid combination.

SSRIs / Fluvoxamine MODERATE

CYP2C19 inhibition increases SSRI plasma levels. Monitor; dose adjustment may be needed.

Contraindicated Populations

Do Not Use

  • Pregnant and lactating women — CBD crosses the placental barrier; neurodevelopmental and reproductive toxicity unresolved; FDA and EFSA state safety cannot be established.
  • Under 25 — EFSA restricts provisional safety dose to adults only due to unresolved endocrine and developmental gaps.
  • Pre-existing liver disease — Compounding hepatotoxic risk at any therapeutic dose; clinical supervision required for any use.
  • Competitive athletes — 21–35% of commercial products contain undisclosed THC; WADA strict liability means the athlete is fully responsible regardless of label claims. "CBD is WADA-permitted" is technically true; the product you buy probably isn't.
  • Immunosuppressant users — CYP3A4 interaction creates organ toxicity risk.

Safety Limits

GuidelineLimitSource
EFSA Provisional ADI (2025) 2 mg/day (70kg adult, ≥98% isolate) EFSA Novel Food Safety Assessment
Henderson et al. Upper Limit (2023) 70 mg/day Food & Chemical Toxicology — reproductive safety margins
Hepatotoxicity threshold (clinical) ~400 mg/day — 5.6% ALT/AST >3× ULN Florian 2025, JAMA Internal Medicine (RCT N=201)
Effective anxiolytic dose 300–600 mg single dose Masataka 2019; Crippa 2021

Critical: The only dose range with clinical anxiolytic evidence (300–600mg) violates EFSA's ADI by 150–300× and falls at or above the confirmed hepatotoxicity threshold. There is no currently established safe chronic daily dose that also produces measurable clinical effect.

§12 — Conviction

Conviction: LOW

Exception: MODERATE for acute situational anxiety at 300mg, single-dose only

Overall conviction is LOW because OTC doses have no demonstrated mechanism, chronic daily use is ruled out by hepatotoxicity data, pain monotherapy fails on effect size, and the sleep claim is dominated by a safer, cheaper alternative.

The MODERATE carve-out stands: 300mg single-dose CBD has two well-designed RCTs behind it for diagnosed SAD. This is a real effect — but it is narrow, requires a clinical-grade compound, and is not safe for daily use.

What would change this conviction

A Phase III, adequately powered, long-term (6+ month) RCT using standardised water-soluble CBD at intermediate OTC doses (75–150mg/day) in a diagnosed population — either Generalised Anxiety Disorder or chronic neuropathic pain — with bi-weekly liver enzyme monitoring and objective biomarker tracking (actigraphy for sleep, validated pain scale for analgesia). The trial must demonstrate both chronic liver safety at these doses AND clinical efficacy above the MCID threshold. Without this, no firm recommendation for OTC daily use can be made.

The regulatory trajectory is moving away from CBD: EFSA 2025's 2mg/day ADI and the Florian 2025 JAMA hepatotoxicity trial are paradigm-shifting in the wrong direction for the supplement industry.

§7 — Where Studies Disagree

The Debate

The Anxiety Paradox — Who Actually Benefits?

Masataka 2019 + Crippa 2021

300mg/day over 4 weeks significantly reduces Social Anxiety Disorder symptoms in clinically diagnosed populations.

VS

Lichenstein 2022 Meta-Analysis

No consistent anxiolytic effects in healthy populations. No benefit in cocaine use disorder. Mixed results across populations.

Why they disagree: Target population. CBD follows a bell-shaped dose curve. Clinically diagnosed SAD responds; healthy adults taking it for background stress don't show the same effect at equivalent doses. The OTC anxiety market is overwhelmingly not the population these trials enrolled.

Sleep — Subjective vs Objective Measurement

Shannon 2019 (160mg)

Participants reported increased sleep duration and improved sleep quality vs placebo over several weeks.

VS

Multiple Actigraphy Studies

Objective sleep tracking shows no significant difference in sleep architecture, duration, or quality compared to placebo at 150mg/day for 2 weeks.

Why they disagree: Measurement tool. Subjective sleep questionnaires capture the feeling of being less anxious at bedtime — which CBD does produce at sufficient doses. Objective actigraphy strips out anxiety and measures actual sleep stages directly. CBD changes how you feel about sleep; it does not change how you sleep.

Pain Relief — Observational vs Randomised

Patient Registries & Surveys

Large observational datasets show massive patient-perceived reductions in chronic pain, often reported as clinically meaningful by users.

VS

Wang 2021 BMJ (32 RCTs, N=5,000+)

–0.50cm on a 10cm pain scale from CBD monotherapy — below the 1–2cm minimum clinically important difference.

Why they disagree: Design quality. Observational data cannot control for placebo effect, expectation bias, or undisclosed THC in commercial products. Double-blind RCTs using pharmaceutical-grade CBD isolate consistently show marginal analgesia that fails to meet clinical relevance thresholds.

Current direction: The weight of evidence is moving away from CBD, not toward it. EFSA 2025 and Florian 2025 (JAMA) are paradigm-shifting. The regulatory trajectory is contraction.

§11 — What the Simple Answer Misses

The Nuance

CBD nuance and alternatives

For Sleep

Melatonin dominates the category

0.3–1mg sublingual melatonin taken 60–90 minutes before bed has stronger evidence, a safety profile in a different universe, and costs 5–10% of a comparable CBD product. CBD sleep effects are secondary anxiolysis — the mechanism only works because high-dose CBD reduces anxiety, not because it changes sleep architecture.

For Athletes

The WADA permit is misleading

CBD isolate is technically permitted. But 1 in 4 commercial products contains detectable THC — and WADA strict liability means the athlete bears full responsibility for a positive test, regardless of what the label says. The safer anxiolytic for athletes with performance anxiety: L-theanine 200mg + caffeine, or ashwagandha 600mg/day.

For Chronic Pain

Not a pharmaceutical substitute

The best available evidence — 32 RCTs, 5,000 patients — shows CBD monotherapy produces 0.5cm reduction on a 10cm pain scale. The clinical relevance threshold is 1–2cm. CBD is not a substitute for prescribed analgesia, physiotherapy, or structured rehabilitation for chronic pain.

The One Valid Use Case

Acute situational anxiety — with caveats

Single-dose 300mg CBD for a high-stakes anxiety event (exam, public speaking, diagnosed SAD) has MODERATE evidence. But: isolate only, with a high-fat meal, off CYP-metabolised medications, not pregnant, not an athlete. This is a pharmaceutical-grade compound requiring a clinical-grade risk-benefit calculation.

Cost-Effectiveness

OptionEffective DoseMonthly CostEvidence Strength
CBD isolate oil — acute anxiety 300mg per use (occasional) £20–40 per bottle (~10 doses) MODERATE
Melatonin (sleep — superior alternative) 0.3–1mg sublingual £5–10/month STRONG
CBD OTC general wellness (10–30mg) Sub-therapeutic (no effect) £20–40/month NONE AT THIS DOSE
L-theanine + caffeine (anxiolytic for athletes) 200mg + 100mg pre-performance £10–15/month MODERATE

What Doesn't Work

Skip These — No Evidence at OTC Doses

  • Low-dose OTC CBD for sleep (10–50mg): No trial has shown doses below 160mg alter sleep architecture. 5mg melatonin directly outperforms 15mg CBD (Saleska 2023).
  • CBD for chronic pain: The highest-quality evidence — 32 RCTs, 5,000+ patients — shows 0.5cm VAS reduction. Below any clinically meaningful threshold. Consumer reports are confounded by placebo and undisclosed THC.
  • "THC-free" broad spectrum for athletes: 21–35% of products contain detectable THC under quantitative analysis, regardless of label.
  • Daily CBD for generalised anxiety: Chronic 300mg/day breaches EFSA's ADI by 150× and approaches the confirmed hepatotoxic threshold. The safety ceiling prevents the dose frequency needed for daily anxiety management.
  • CBD gummies: Typical doses of 25–50mg are sub-threshold for any known mechanism. Effectively placebo at standard retail doses.

Cross-Engine Context

Melatonin (2026-03-22)

5mg melatonin directly outperforms 15mg CBD for sleep. For sleep, use 0.3–1mg sublingual melatonin 60–90 min before bed. Not CBD.

Ashwagandha (2026-03-19)

600mg/day KSM-66 ashwagandha is the safer daily cortisol/anxiety adaptogen. MODERATE conviction. No hepatotoxicity ceiling.

Caffeine + L-Theanine (2026-03-22)

L-theanine 200mg + caffeine is the safer athlete anxiolytic alternative. No WADA risk, no hepatotoxicity, MODERATE evidence.

§13 — Sources

Key References

1 Wang et al. (2021) The BMJ — Comparative efficacy and safety of cannabinoids, cannabis, and purified CBD extract in adults with chronic pain. Systematic review of 32 RCTs, N=5,000+.

Key: –0.50cm pain VAS reduction from CBD monotherapy — below 1–2cm MCID. Highest-quality pain evidence available.

2 Florian et al. (2025) JAMA Internal Medicine — Liver injury from cannabidiol in healthy adults. RCT N=201.

Key: 5.6% ALT/AST >3× ULN at 400mg/day in healthy adults within 28 days. No external symptoms — liver injury undetected without monitoring.

3 Crippa et al. (2021) JAMA Network Open — CBD for COVID-19-related burnout. RCT N=120, 300mg/day over 28 days.

Key: Significant anxiolytic and burnout benefit at 300mg/day — supports MODERATE conviction for acute anxiety at therapeutic dose.

4 Masataka N. (2019) Frontiers in Psychology — Anxiolytic effects of CBD in teenagers with Social Anxiety Disorder. RCT N=37.

Key: 300mg/day significant SAD symptom reduction over 4 weeks in clinically diagnosed population. Core evidence for MODERATE conviction carve-out.

5 Saleska et al. (2023) medRxiv — Radicle Science — CBD vs melatonin for sleep disturbance. Pragmatic RCT.

Key: 15mg CBD ≤ 5mg melatonin for sleep improvement. Directly kills CBD sleep claim at typical OTC doses.

6 Henderson et al. (2023) Food & Chemical Toxicology — Acceptable daily intake and tolerable upper intake levels for CBD.

Key: UL 70mg/day based on reproductive safety. ADI 0.43mg/kg (~30mg/70kg).

7 EFSA (2025) — Safety of CBD as a novel food ingredient. Provisional ADI 2mg/day for 70kg adult at ≥98% purity.

Key: Paradigm-shifting regulatory assessment. Effective doses violate ADI by 150–300×. European regulatory trajectory is contraction.

8 Bonn-Miller et al. (2017) JAMA — Labelling accuracy of cannabidiol extracts sold online. N=84 products.

Key: 69% of products mislabelled; 21% contained detectable THC. Foundation of WADA violation risk argument.

Verdict Score

How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.

66 Mixed evidence
80–100Strong evidence
60–79Mixed but supportive ◀
40–59Uncertain
0–39Weak support

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score
32/100 Poor ROI Trust grade D
No for daily sleep, pain, or wellness. The one narrow exception is a single 300mg dose for diagnosed situational anxiety.
Time
Low
Money
Medium
Effort
Low
Risk
High
Why this score
Why it didn’t score higher
Best for
Lower ROI if
Minimum effective dose
300mg isolate, single dose, 60 to 90 minutes before a stressor, taken with a high-fat meal, for diagnosed situational anxiety only. No effective daily dose exists below the hepatotoxicity threshold.
Track this

Get the complete dosing protocol

Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.

Get the protocol

Related free research

Supplements
Plant Sterols & Stanols — The Verdict
 Supplements
Exogenous Ketones — The Verdict
 Supplements
Serrapeptase — Does the Silkworm Enzyme Actually Work?

There are 424 more inside

Conviction-scored verdicts on supplements, nutrition, training, physio, and recovery.

Explore all Get weekly verdicts